Kristen Oelschlager Sells 12,678 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) COO Kristen Oelschlager sold 12,678 shares of Castle Biosciences stock in a transaction that occurred on Friday, October 31st. The shares were sold at an average price of $25.04, for a total transaction of $317,457.12. Following the sale, the chief operating officer owned 27,569 shares of the company’s stock, valued at approximately $690,327.76. The trade was a 31.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Castle Biosciences Stock Up 6.1%

NASDAQ:CSTL opened at $33.57 on Thursday. The firm has a market capitalization of $979.91 million, a P/E ratio of -74.60 and a beta of 1.12. The company’s fifty day moving average price is $23.68 and its 200-day moving average price is $20.26. Castle Biosciences, Inc. has a 1-year low of $14.59 and a 1-year high of $34.64. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.47 and a quick ratio of 6.69.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings results on Monday, November 3rd. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.32. The company had revenue of $83.04 million for the quarter, compared to analyst estimates of $71.06 million. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.73%. Castle Biosciences has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Castle Biosciences, Inc. will post 0.44 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on CSTL. Wall Street Zen upgraded Castle Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 10th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $37.00 target price on shares of Castle Biosciences in a report on Tuesday, September 9th. Zacks Research raised shares of Castle Biosciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Castle Biosciences in a research report on Thursday, October 30th. Finally, BTIG Research lifted their price objective on shares of Castle Biosciences from $32.00 to $38.00 and gave the company a “buy” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $37.43.

Hedge Funds Weigh In On Castle Biosciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CSTL. Allspring Global Investments Holdings LLC increased its stake in shares of Castle Biosciences by 2,070.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 217,794 shares of the company’s stock worth $4,360,000 after purchasing an additional 207,761 shares in the last quarter. Teacher Retirement System of Texas boosted its holdings in Castle Biosciences by 9.6% in the 1st quarter. Teacher Retirement System of Texas now owns 10,383 shares of the company’s stock worth $208,000 after buying an additional 908 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in Castle Biosciences by 2.2% in the 1st quarter. Principal Financial Group Inc. now owns 1,467,873 shares of the company’s stock worth $29,387,000 after buying an additional 32,208 shares during the last quarter. Cerity Partners LLC purchased a new stake in Castle Biosciences during the 1st quarter worth approximately $423,000. Finally, Diversify Wealth Management LLC raised its holdings in shares of Castle Biosciences by 5.8% during the first quarter. Diversify Wealth Management LLC now owns 13,102 shares of the company’s stock valued at $260,000 after acquiring an additional 717 shares during the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.